Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supplement GMPs Should Proceed Despite Economic Concerns - CRN, Rexall

This article was originally published in The Tan Sheet

Executive Summary

Concerns over the economic burden that small companies will face when implementing Good Manufacturing Practices for dietary supplements should not delay or unduly affect FDA's rulemaking, industry commenters advise.

You may also be interested in...



Supplement Manufacturing Practices Survey Proposed By FDA

FDA is proposing to conduct a survey of dietary supplement companies' existing manufacturing practices for use in developing its proposed rule on industry-wide GMP standards, the agency says in an Oct. 6 Federal Register notice.

CFSAN Visiting Supplement Companies For Information On Developing GMPs

FDA representatives have visited three dietary supplement manufacturing facilities the last two months and will visit three more the week of Sept. 30 to better understand the manufacturing practices of the supplement industry. The information gathered during the visits will be used as the agency develops its proposed rule for dietary supplement Good Manufacturing Practices.

Nature's Way, Wakunaga Receive First NNFA GMP Certifications

All Nature's Way dietary supplements will carry the NNFA good manufacturing practices logo on their protective seal or shrink-wrap by mid-September. The seal may be incorporated directly onto the company's packaging when future labeling changes or line extensions are introduced, according to the firm.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS090567

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel